Details for Patent: 8,269,040

Which drugs does patent 8,269,040 protect, and when does it expire?

Patent 8,269,040 protects PRISTIQ and is included in one NDA.

This patent has twenty-two patent family members in sixteen countries.

Summary for Patent: 8,269,040

Title:	Derivatives of venlafaxine and methods of preparing and using the same
Abstract:	Methods of preparing, and compositions comprising, derivatives of venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.
Inventor(s):	Jerussi; Thomas P. (Framingham, MA), Senanayake; Chrisantha H. (Shrewsbury, MA), Bhongle; Nandkumar N. (Shrewsbury, MA)
Assignee:	Wyeth LLC (Madison, NJ)
Application Number:	10/720,134
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,269,040
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 8,269,040

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pf Prism Cv	PRISTIQ	desvenlafaxine succinate	TABLET, EXTENDED RELEASE;ORAL	021992-003	Aug 20, 2014	AB	RX	Yes	No				Y
Pf Prism Cv	PRISTIQ	desvenlafaxine succinate	TABLET, EXTENDED RELEASE;ORAL	021992-001	Feb 29, 2008	AB	RX	Yes	No				Y
Pf Prism Cv	PRISTIQ	desvenlafaxine succinate	TABLET, EXTENDED RELEASE;ORAL	021992-002	Feb 29, 2008	AB	RX	Yes	Yes				Y

International Family Members for US Patent 8,269,040

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	397581
Australia	2005218047
Australia	4062700